A systematic review published in JAMA Oncology synthesizes economic evaluations of adjuvant immunotherapy for cancer. It assesses the cost-effectiveness of these treatments, the gains in quality-adjusted life-years (QALYs) they provide, and the methodological approaches used in such analyses.
Why it might matter to you:
As advanced therapies become standard in oncology, understanding their economic impact is crucial for healthcare systems and clinical decision-making. This review provides a framework for evaluating the value proposition of new treatments, a consideration that increasingly intersects with clinical practice and research funding priorities.
A Nanogel Strategy to Starve Tumours and Boost Immunity
Researchers report on a novel thermosensitive nanogel that targets the CD36 receptor to block tumors from hijacking lipids, a key energy source. In models of triple-negative breast cancer, this approach not only starved the tumor but also significantly enhanced the effectiveness of anti-PD-L1 immunotherapy, suggesting a powerful combination strategy.
Why it might matter to you:
This work highlights an emerging frontier in oncology: targeting tumor metabolism to overcome treatment resistance. The dual-action mechanism—disrupting a fundamental cancer survival pathway while potentiating immunotherapy—represents a sophisticated, multi-target therapeutic paradigm relevant to the development of next-generation interventions.
Charting the Course: The 2026 Landscape of Cancer
The American Cancer Society’s flagship journal, CA: A Cancer Journal for Clinicians, has released its authoritative “Cancer Statistics, 2026” report. This annual publication provides a comprehensive overview of current cancer trends, burdens, and survival data, and is used to inform and set the agenda for national cancer research priorities.
Why it might matter to you:
This report is a foundational resource for understanding the evolving epidemiology of cancer. It offers critical, data-driven context that can shape research questions, guide public health strategy, and highlight disparities in outcomes—essential knowledge for any professional engaged in the broader oncology landscape.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.